Explore our service offerings and discover how we can help you unlock your aesthetic potential
Cagrilintide monotherapy for treatment of obesity In a 26-week phase 2 trial (n=706, 62 Percentage women, mean age 52 years), cagrilintide was evaluated in 5 groups of subjects receiving 0.3, 0.6, 1.2, 2.4, and 4.5 mg/week as treatment for obesity in comparison with liraglutide 3.0 mg/day, and placebo (table 1) [9]
Sikiric et al., 1997b
Reconstituted solution is more vulnerable because hydrolysis, contamination risk, temperature swings, and repeated vial access all become more important
Use clinic details for directions, booking, and local information, then bring any prior lab work or treatment plans that help the visit move faster
These treatments all remain available today, and I will discuss them in greater detail below